Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions

Botulism

Interventions

BIOLOGICAL

rBV A/B

Recombinant Botulinum Vaccine A/B, rBV A/B

Trial Locations (2)

Battelle Biomedical Research Center, West Jefferson

California Department of Public Health, Richmond

All Listed Sponsors

lead

California Department of Public Health

OTHER

NCT06112834 - Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG® | Biotech Hunter | Biotech Hunter